Sugi Predict

Sugi Predict / Compounds / Sucrosofate

Sucrosofate

Sucrosofate

SCHEMBL3086839

O=S(=O)([O-])OC[C@H]1O[C@@](COS(=O)(=O)[O-])(O[C@H]2O[C@H](COS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]2OS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@@H]1OS(=O)(=O)[O-].O=S(=O)([O-])OC[C@H]1O[C@@](COS(=O)(=O)[O-])(O[C@H]2O[C@H](COS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]2OS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@@H]1OS(=O)(=O)[O-].O=S(=O)([O-])OC[C@H]1O[C@@](COS(=O)(=O)[O-])(O[C@H]2O[C@H](COS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]2OS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@@H]1OS(=O)(=O)[O-].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TOP1

The experimentally established mechanism targets of Sucrosofate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ HPSE Q9Y251 17/20 0.52
▸ FGF1 P05230 9/20 0.48
▸ FGF2 P09038 7/20 0.48
▸ VEGFA P15692 6/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sucrosofate SCHEMBL28961186 0.98 HPSE (0.55) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL15653532 0.98 HPSE (0.52) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL15485823 0.98 HPSE (0.52) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL7325451 0.98 HPSE (0.55) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL8699894 0.97 HPSE (0.54) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL16661861 0.79 FGF1 (0.74) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL145070 0.79 FGF1 (0.74) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL18467935 0.79 FGF1 (0.74) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL145069 0.79 FGF1 (0.74) HPSEFGF1FGF2VEGFA
Sucrosofate SCHEMBL16661862 0.79 FGF1 (0.74) HPSEFGF1FGF2VEGFA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104284651-A Formulations comprising caprylic and/or capric ethanolamide in combination with aluminium salts and uses thereof EVONIK INDUSTRIES AG 2015-01-14 — — CN claimed
CN-113423379-B Complexes for transdermal delivery using metal-organic matrix materials and triblock copolymers H&A帕玛科株式会社 2023-11-17 — — CN disclosed
CN-116669694-A Cosmetic composition 株式会社LG生活健康 2023-08-29 — — CN disclosed
CN-116669694-A Cosmetic composition 株式会社LG生活健康 2023-08-29 — — CN disclosed
CN-111526857-B Complexes for transdermal delivery using metal-organic framework materials and nanocellulose H&A帕玛科株式会社 2023-07-04 — — CN disclosed
CN-116262771-A Synthesis method of sucrose octasulfate 辅必成（上海）医药科技有限公司 2023-06-16 — — CN disclosed
CN-115066229-A Complexes for transdermal delivery utilizing covalent organic matrix materials and polymers H&A帕玛科株式会社 2022-09-16 — — CN disclosed
CN-113423379-A Composites for transdermal delivery utilizing metal-organic matrix materials and triblock copolymers H&A帕玛科株式会社 2021-09-21 — — CN disclosed
CN-110741012-A Synthesis method of sucralfate and sucralfate prepared by method 韩国普莱姆制药株式会社 2020-01-31 — — CN disclosed
US-20170127675-A1 COMPOSITIONS AND METHODS FOR CONTROLLING INSECT POPULATIONS OLFACTOR LABORATORIES, INC. (US) 2017-05-11 — — US disclosed
US-20130274209-A1 SPRAYABLE PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING SUCRALFATE GEL Laboratoria Italiano Biochimico Farmaceutico Lisapharma S.P.A. (IT) 2013-10-17 — — US disclosed
WO-2012085859-A1 SPRAYABLE PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING SUCRALFATE GEL LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A. (IT) 2012-06-28 — — WO disclosed
US-7795239-B2 Saccharide compositions and method of use Mueller Medical International LLC (KN) 2010-09-14 — — US disclosed
US-20090011991-A1 Novel Curcuminoid-Factor VIIA Constructs as Suppressors of Tumor Growth and Angiogenesis EMORY UNIVERSITY 2009-01-08 — — US disclosed
US-20050112213-A1 Compositions of improved sucralfate and sucrose octasulfate and method of use MCCULLOUGH, JOANNE 2005-05-26 — — US disclosed
US-20040023864-A1 Method of regulating angiogenesis using ryk protein ROCZNIAK STEVE 2004-02-05 — — US disclosed
EP-1287121-A2 EXTRACELLULAR DOMAIN OF RYK PROTEIN FOR REGULATING ANGIOGENESIS Bayer Corporation (US) 2003-03-05 — — EP disclosed
WO-2001085789-A2 EXTRACELLULAR DOMAIN OF RYK PROTEIN FOR REGULATING ANGIOGENESIS BAYER CORPORATION (US) 2001-11-15 — — WO disclosed
US-5447918-A And antacid MCCULLOUGH, JOANNE 1995-09-05 — — US disclosed
US-4990610-A Reacting Sucrose with Chlorosulfonic acid and 2-Picoline APPLIED ANALYTICAL INDUSTRIES, INC. (US) 1991-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274209-A1 SPRAYABLE PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING SUCRALFATE GEL SUCLG1, SUCLG2, SORD HPSE 1458/4885FGF1 1719/4885FGF2 635/4885
US-20090011991-A1 Novel Curcuminoid-Factor VIIA Constructs as Suppressors of Tumor Growth and Angiogenesis F13B, F13A1, HABP2 HPSE 1184/4885FGF1 905/4885FGF2 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.